Cumberland Pharmaceuticals (NASDAQ:CPIX) had its price objective boosted by research analysts at B. Riley from $9.00 to $9.75 in a report released on Tuesday, BenzingaRatingsTable reports. The firm currently has a “buy” rating on the specialty pharmaceutical company’s stock. B. Riley’s target price would suggest a potential upside of 79.89% from the stock’s current price.
A number of other equities analysts also recently commented on the stock. Zacks Investment Research downgraded shares of Cumberland Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Thursday, November 21st. ValuEngine cut shares of Cumberland Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Monday, November 4th.
Cumberland Pharmaceuticals stock opened at $5.42 on Tuesday. The business has a fifty day moving average of $5.22 and a two-hundred day moving average of $5.66. The company has a quick ratio of 1.88, a current ratio of 2.35 and a debt-to-equity ratio of 0.39. The firm has a market cap of $72.73 million, a P/E ratio of -45.17 and a beta of 0.10. Cumberland Pharmaceuticals has a twelve month low of $4.19 and a twelve month high of $6.99.
Cumberland Pharmaceuticals (NASDAQ:CPIX) last announced its quarterly earnings results on Tuesday, November 12th. The specialty pharmaceutical company reported $0.01 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $0.11 by ($0.10). The company had revenue of $10.37 million during the quarter, compared to analysts’ expectations of $12.65 million. Cumberland Pharmaceuticals had a negative net margin of 10.13% and a positive return on equity of 6.76%. Equities analysts expect that Cumberland Pharmaceuticals will post 0.15 earnings per share for the current year.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Financial Gravity Wealth Inc. acquired a new position in shares of Cumberland Pharmaceuticals during the third quarter worth $36,000. Dalton Greiner Hartman Maher & Co. purchased a new stake in Cumberland Pharmaceuticals in the third quarter valued at about $528,000. BlackRock Inc. raised its stake in Cumberland Pharmaceuticals by 17.2% in the second quarter. BlackRock Inc. now owns 332,543 shares of the specialty pharmaceutical company’s stock valued at $2,118,000 after buying an additional 48,753 shares during the last quarter. Renaissance Technologies LLC boosted its holdings in Cumberland Pharmaceuticals by 13.0% in the second quarter. Renaissance Technologies LLC now owns 441,577 shares of the specialty pharmaceutical company’s stock worth $2,813,000 after acquiring an additional 50,800 shares in the last quarter. Finally, Acadian Asset Management LLC boosted its holdings in Cumberland Pharmaceuticals by 6.9% in the second quarter. Acadian Asset Management LLC now owns 104,498 shares of the specialty pharmaceutical company’s stock worth $665,000 after acquiring an additional 6,765 shares in the last quarter. 29.52% of the stock is currently owned by institutional investors and hedge funds.
About Cumberland Pharmaceuticals
Cumberland Pharmaceuticals Inc, a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and oncology markets in the United States and internationally. It offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative, for the treatment of chronic and acute constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol injection for treating hyponatremia; Ethyol injection for the reduction of xerostomia; Totect injection, for emergency oncology intervention, to treat the toxic effects of anthracycline chemotherapy; and Vibativ injection, for the treatment of certain serious bacterial infections.
Featured Article: Does the Step Transaction Doctrine Affect a Backdoor Roth IRA?
Receive News & Ratings for Cumberland Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cumberland Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.